W. Li

Shandong University, Chi-nan-shih, Shandong Sheng, China

Are you W. Li?

Claim your profile

Publications (8)10.16 Total impact

  • W. Li · J.F. Fei · Q. Yang · B.L. Li · C. Lin · Q. Yue · Q.G. Meng ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to observe the acute cytotoxic effects of hematoporphyrin monomethyl ether sonodynamic therapy (HMME-SDT) on hypertrophic scar fibroblasts of rabbit ears. We first assessed the effects of different irradiation times and HMME concentrations on the survival of hypertrophic scar fibroblasts using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to determine the optimum irradiation time and HMME concentration. The hypertrophic scar fibroblast cell suspensions of the rabbit ears were divided into four groups, the survival rates were detected using the MTT assay, and the type of cell death was detected by Annexin V/propidium iodide (PI) double staining flow cytometry. Our results showed that HMME-SDT significantly reduced the viability of hypertrophic scar fibroblasts of rabbit ears at ultrasonic irradiation times of 30, 60, and 90 s, but not 10 s (P < 0.05). HMME alone had no significant effect on the cell survival rate at any irradiation time (P > 0.05). In contrast, the cell survival rate was significantly decreased at an irradiation time of 10 s and HMME concentrations of 20 and 50 μg/mL (P < 0.05). Furthermore, Annexin V/PI double staining showed necrosis and apoptosis of the hypertrophic scar fibroblasts. Given our results, HMME might be an effective sound-sensitive agent for SDT as it has a significant lethal effect on hypertrophic scar fibroblasts of rabbit ear cultured in vitro. HMME-SDT may therefore provide a new method for the treatment of hypertrophic scar formation.
    Genetics and molecular research: GMR 05/2015; 14(2):4203-4214. DOI:10.4238/2015.April.28.3 · 0.78 Impact Factor
  • Y. Li · F. Han · S. Yin · X. Yang · W. Li · Z. Qu · J. Bi · Y. Cheng · Q. Yue ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Sonodynamic therapy (SDT) based on the power of ultrasonic can activate sonosensitizing drug (sonosensitizer) in tumor tissues to cure diseases, which was developed in Japan in recent decades and have characteristics including safe, effective, low toxic and low side effects. This article aims to have a brief description and discussion about SDT research progress in recent decades and give attention and awareness.
    Cancer Research and Clinic 03/2015; 27(3):204-206. DOI:10.3760/cma.j.issn.1006-9801.2015.03.019
  • Source
    J Ren · W Li · L Yan · W Jiao · S Tian · D Li · Y Tang · G Gu · H Liu · Z Xu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancerous inhibitor of protein phosphatase 2A (CIP2A) drives cellular transformation. The objective of this study was to detect the potential effects of CIP2A in renal cell carcinomas (RCCs). A total of 107 RCC patients were involved in the study. Cancerous inhibitor of protein phosphatase 2A expression was investigated by real-time PCR and immunohistochemistry. In vitro, we examined the expression of CIP2A and c-Myc and tested the migration and invasion capability of A498 and KRC/Y cells with scratch migration assay and Matrigel invasion assay after down-regulating CIP2A expression using siRNA. Cancerous inhibitor of protein phosphatase 2A was over-expressed in RCC tissues. Clear cell RCC showed an even higher-CIP2A expression level than papillary or chromophobe RCC did. The CIP2A immunostaining level was positively correlated with primary tumour stage, lymph node metastasis, distant metastasis, TNM stage and histological grade (all P<0.05). High-CIP2A expression implied poor survival for patients (P<0.05). Cancerous inhibitor of protein phosphatase 2A depletion by siRNA down-regulated c-Myc expression and attenuated the migration and invasion of RCC cells. Higher-CIP2A expression positively correlates with the aggressive phenotype of RCCs, and predicts poor prognosis for patients. Cancerous inhibitor of protein phosphatase 2A may be a novel target for prevention and treatment of RCC metastasis and recurrence.
    British Journal of Cancer 11/2011; 105(12):1905-11. DOI:10.1038/bjc.2011.492 · 4.84 Impact Factor
  • Source
    G Gu · Z Zhang · G Wang · F Han · L Han · K Wang · J Liu · W Li ·
    [Show abstract] [Hide abstract]
    ABSTRACT: This study investigated the effect of electroacupuncture pretreatment on the lipopolysaccharide (LPS)-induced inflammatory response and on acute kidney injury in adult male pathogen-free Wistar rats. Rats received electroacupuncture at the Zusanli (ST36) and Neiguan (PC6) acupoints, or electrical stimulation at sham points, for 30 min before stimulation with either 5 mg/kg LPS intravenously or normal saline. Plasma cytokines, plasma nitrite, renal inducible nitric oxide synthase (iNOS) and nuclear factor κB (NF-κB) activity were assessed 240 min after LPS or normal saline injection. Blood urea nitrogen (BUN), creatinine (Cr) and histopathological score for renal tubular damage were also measured. Electroacupuncture pretreatment significantly decreased LPS-induced plasma tumour necrosis factor-α and interleukin (IL)-1β, increased plasma IL-10, and decreased plasma nitrite, renal iNOS and NF-κB activity. It also significantly decreased LPS-induced BUN, Cr and the renal histopathological score. These findings suggest that electroacupuncture pretreatment at the ST36 and PC6 acupoints attenuated the LPS-induced inflammatory response and mitigated acute kidney injury.
    The Journal of international medical research 10/2011; 39(5):1783-97. DOI:10.1177/147323001103900521 · 1.44 Impact Factor
  • W Li · W J Yue · Q Yue · D W Yang · Q G Meng ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The therapeutic value of the transforming growth factor beta 1 (TGF-b) in transplantation has been reported; However, cell-mediated gene therapy using TGF-b is not applied to the organ transplantation widely. This study was to evaluate whether TGF-b-modified donor spleen cell specific transfusion in rat heterotopic allo-limb transplantation could induce tolerance tolerogenicity and prolong allograft's survival time. The Splenic T-cell in Wistar rats responsing to donor spleen cells which received TGF-b-transduced were severely impaired.The Survival time of Sprague-Dawley Allograft-limb in Wistar rats given TGF-b-modified donor spleen cells (5¥106 cells/well, administration of donor TGF-b-transduced donor spleen cells 7 days before transplantation) was extended modestly but significantly.
    Panminerva medica 12/2010; 52(4):289-95. · 1.67 Impact Factor
  • Source
    W Li · Y-Y Lian · W-J Yue · Q Yang · Q Yue · Q-G Meng · C-B Zhao ·
    [Show abstract] [Hide abstract]
    ABSTRACT: This study investigated the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on peri-operative blood loss during elective total hip replacement. Patients were randomized to receive enteric-coated diclofenac 50 mg (n = 18), rofecoxib 12.5 mg (n = 17) or placebo (n = 16) administered orally three times daily for 2 weeks prior to surgery. Severe adverse effects resulting in discontinuation of trial participation occurred in six patients in the diclofenac group, five patients in the rofecoxib group and two patients in the placebo group; all drop-outs occurred at various times after surgery. Compared with placebo, peri-operative blood loss increased by 32% in the diclofenac group and by 7% in the rofecoxib group. Total mean +/- SD blood loss was 1040 +/- 136 ml in the diclofenac group, 844 +/- 83 ml in the rofecoxib group and 789 +/- 82 ml in the placebo group. Thus, administering a non-selective NSAID 2 weeks prior to elective total hip replacement significantly increases peri-operative blood loss.
    The Journal of international medical research 03/2009; 37(2):472-8. DOI:10.1177/147323000903700223 · 1.44 Impact Factor
  • B.Q. Gong · W.L. Liu · W.C. Qi · F. Han · W. Li ·

  • F.R. Li · J.X. Yang · B.L. Li · Z.T. Zhang · W. Li ·

Publication Stats

42 Citations
10.16 Total Impact Points


  • 2011
    • Shandong University
      • School of Medicine
      Chi-nan-shih, Shandong Sheng, China
  • 2009-2011
    • Harbin Medical University
      • Department of Orthopedic Surgery
      Charbin, Heilongjiang Sheng, China